0ME Stock Overview
Manufactures and sells synthetic DNA-based products. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Twist Bioscience Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.28 |
| 52 Week High | US$53.20 |
| 52 Week Low | US$25.78 |
| Beta | 1.84 |
| 1 Month Change | 6.15% |
| 3 Month Change | n/a |
| 1 Year Change | 28.44% |
| 3 Year Change | -41.97% |
| 5 Year Change | 106.40% |
| Change since IPO | 252.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0ME | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.7% | -3.5% | -2.0% |
| 1Y | 28.4% | -14.7% | 6.9% |
Return vs Industry: 0ME exceeded the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 0ME exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| 0ME volatility | |
|---|---|
| 0ME Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0ME's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0ME's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 923 | Emily Leproust | www.twistbioscience.com |
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution.
Twist Bioscience Corporation Fundamentals Summary
| 0ME fundamental statistics | |
|---|---|
| Market cap | €2.73b |
| Earnings (TTM) | -€200.04m |
| Revenue (TTM) | €299.95m |
9.1x
P/S Ratio-13.6x
P/E RatioIs 0ME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0ME income statement (TTM) | |
|---|---|
| Revenue | US$312.97m |
| Cost of Revenue | US$179.63m |
| Gross Profit | US$133.35m |
| Other Expenses | US$342.08m |
| Earnings | -US$208.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.52 |
| Gross Margin | 42.61% |
| Net Profit Margin | -66.69% |
| Debt/Equity Ratio | 0% |
How did 0ME perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 20:05 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Twist Bioscience Corporation is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Gaurav Goparaju | Berenberg |